The hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer market was worth $3.4bn across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) in 2015, according to new Datamonitor Healthcare estimates. This figure is forecast to steadily increase, reaching a peak of $10.7bn in 2022 before falling back down to $9.6bn in 2024.
Despite the drop off in the last two years of the forecast, the market is projected to increase at a compound annual growth rate (CAGR) of 12% over 2015–24.